When translational researchers, drug developers, and clinical scientists seek immuno-oncology (IO) foresight, they often find it in biomarkers—or better still, the patterns formed by multiple biomarkers. Single biomarkers convey little of cancer’s complexity, leaving much unclear about the signaling pathways that sustain or suppress malignancies, the mechanisms that activate or deactivate specific immune defenses, or […]
The post Signs, Portents, and Immuno-Oncology Biomarkers appeared first on GEN - Genetic Engineering and Biotechnology News.
Original Article: Signs, Portents, and Immuno-Oncology Biomarkers